JOE FARAGO

Executive Director, Private Payers and Investment

IMC

In January 2016, Joe joined the Innovative Medicines Canada association. Currently, Joe is the Executive Director Private Payers and Investment, responsible for the private payer market, pCPA and the national innovation strategy.

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. The membership consists of more than 50 companies that advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians.

Joe is leading the pharmaceutical sectors efforts in taking a more proactive, research-based approach to addressing today’s policy issues. Part of his efforts include being an advocate for Canada’s dual market of private and public coverage ensuring employees and their families have timely access to innovative medicine to help keep them healthy and productive.

Over the last 30+ years Joe has acquired a vast knowledge of the Canadian Pharmaceutical and Specialty Biopharmaceutical markets. He has a wide range of experience in market access, government affairs, sales, marketing and operations. Joe has had the opportunity to be part of establishing two organizations in the Canadian market from the ground up and brings a strong understanding of market access success and organizational development. Joe started his pharmaceutical career with Servier Canada in 1989 until he entered the Plasma Protein Specialty market with CSL Limited in 2007 where he was instrumental in establishing and building the Canadian organization to a market leader.

Joe Farago attended Carleton University, graduating with a BSc.

Joe lives in Manotick, Ontario with his wife and their three children.


All Sessions by JOE FARAGO

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

3:15 pm

3:15 pm

PANEL DISCUSSION: PRIVATE PAYERS’ PERSPECTIVE

Pathways to Access & Reimbursement for Private Payers

Continued tightening of access to private payer formularies combined with a move to outsource benefit plans and administration to third parties for some payers, means an increase in barriers to listings. Benefit plans are the pathway to accessing medications for almost two thirds of Canadians:
·        Understand TELUS Health’s review process for managed formularies.
·        Learn how pharma companies can better align their submissions to private payor needs.
·        Gain insight into private group insurance plans and current trends

Learn about important processes being used to gain drug listing and understand how the private payer market in Canada is evolving. 

Agenda: Day 2 Oct 6, 2020